Mango Medical

Roadmap & Position in Orthopedic Surgery

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Company Overview

Builds an agentic AI planning platform that processes CT scans to automate and personalize preoperative planning for orthopedic surgeries, starting with shoulder arthroplasty.

What They're Building

The company's public product roadmap & what they're committed to building.

Mango Medical has publicly indicated an initial product focus on instant, AI-driven surgical planning for shoulder arthroplasty via API, with active pursuit of FDA 510(k) clearance. Their YC profile highlights an 8-figure letter of intent from a leading orthopedic company, signaling near-term commercial deployment. They have publicly reported surpassing $500K ARR before Demo Day. Expansion to additional joint replacement procedures (hip, knee) and acute fracture planning is implied by company positioning and market messaging.

Latest Intelligence

Zeitgeist tracks private signals to determine where the company is heading strategically.

Orthopedic Planning Moves Toward Surgical Guidance

May 13, 2026

Confidence:

High

New Intel: Mango Medical is automating orthopedic surgical planning from CT scans, starting with shoulder arthroplasty. The 8-figure LOI suggests a serious path into medical device distribution and training data.

Founder and Key Execs

Adrian Kilian, Co-Founder & CEO

Co-Founder & CEO

Jorge Padilla Pérez, Co-Founder

Co-Founder

Founder Force Multiplier

This gives them a proprietary data flywheel and distribution channel that pure-play AI companies and legacy planning tools cannot easily replicate, reinforced by $500K+ ARR achieved before Demo Day.

Funding History

2020 | Adrian Kilian and Jorge Padilla Pérez co-found Mango Medical in Freising, Germany.
2026 | Accepted into Y Combinator Winter 2026 batch (only company pursuing FDA approval for a MedTech product in the batch).
2026 | Secured 8-figure LOI from a leading orthopedic company.
2026 | Surpassed $500K ARR before Demo Day.
2026 | Pursuing FDA 510(k) clearance for shoulder arthroplasty planning.

Competitors

Legacy Surgical Planning

Materialise (Mimics), Stryker (Blueprint 3D), Zimmer Biomet (Signature Solutions), Smith+Nephew (CORI).

AI-Native Surgical Planning

Formus Labs (hip/knee AI planning), Bodycad (patient-specific implants + AI), Enhatch (AI surgical planning platform).

Adjacent AI Medical Imaging

Imagen Technologies, Aidoc, Viz.ai (radiology AI, not orthopedic-specific).

Mango Medical

's Moat:

$500K+ ARR pre-demo day and an 8-figure LOI from a leading orthopedic company. FDA 510(k) clearance pursuit creates a regulatory barrier that delays competitors by 1-2 years. Each surgical plan processed trains the AI on anatomy-specific patterns, building a dataset that improves precision planning for future cases.

How They're Leveraging AI

3D CT Scan Segmentation

Automated 3D bone segmentation and anatomical landmark detection from CT scans to generate patient-specific surgical plans in seconds.

Agentic Implant Optimization

Agentic AI surgical planning that autonomously selects optimal implant size, position, and orientation based on patient anatomy and surgical goals.

Surgical Outcome Prediction

Predictive analytics and outcome modeling that forecasts post-surgical biomechanical performance and complication risk to guide plan selection.

AI Use Overview:

Using 3D CT scan segmentation for bone modeling, agentic implant optimization for patient-specific planning, and surgical outcome prediction from historical data.

More Similar Companies

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Origin

Designs regulatory DNA that outperforms DeepMind for safer, more precise gene therapies.

Gene therapies need precise regulatory DNA elements to control where and when genes express. Origin's Axis model outperforms DeepMind's AlphaGenome by 6.7% on activity prediction, with free API access for researchers and pharma partnerships forming.

Back To All Companies >